Bryce Joanne 4
4 · Disc Medicine, Inc. · Filed Aug 3, 2023
Insider Transaction Report
Form 4
Bryce Joanne
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-08-01$1.01/sh+4,521$4,566→ 5,781 total - Sale
Common Stock
2023-08-01$49.63/sh−3,067$152,213→ 2,714 total - Sale
Common Stock
2023-08-01$50.50/sh−1,454$73,420→ 1,260 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-08-01−4,521→ 1,507 totalExercise: $1.01Exp: 2029-11-05→ Common Stock (4,521 underlying)
Footnotes (4)
- [F1]he transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 15, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.14 to $50.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.15 to $50.85, inclusive.
- [F4]The shares underlying this option vest in 16 equal quarterly installments following May 1, 2020, subject to the Reporting Person's continued service on each such vesting date.